FLGT - Fulgent Mission team up for single-cell multi-omics for drug development

2023-04-11 10:05:56 ET

• Fulgent Genetics ( NASDAQ: FLGT ) and Mission Bio are collaborating to broaden accessibility of single-cell multi-omics for drug development and clinical research.
• Fulgent said it is now able to offer single-cell multi-omics on the Tapestri Platform on its services, including whole genome, whole exome, RNA sequencing, tumor profiling, methylation sequencing, liquid biopsy, single-cell sequencing, spatial biology, and pathology to support its pharma client demands.
• Fulgent added that it will evaluate the Tapestri Platform for applications in clinical development to streamline drug development and approval process.
• "While some pharma customers can and still do partner with us through our internal Pharma Assay Development (PAD) services, this collaboration provides another option for them to leverage the single-cell multi-omics expertise and full suite of solutions offered by Fulgent Genetics, particularly as they complete the validation of the Tapestri Platform in their CAP CLIA lab in the near future," said Mission Bio's Chief Medical Officer Todd Druley.

For further details see: